About: Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5 Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 05 October 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2019 (fr) artículu científicu espublizáu n'ochobre de 2019 (ast) scientific article published on 05 October 2019 (en) наукова стаття, опублікована 5 жовтня 2019 (uk)
publication date	wds:Q90502051-DD986D62-DA57-428A-85AB-38401ADB6221
publication date	2019-10-05 00:00:00Z (xsd:dateTime)
cites work	wds:Q90502051-022DC420-1ACB-4AFE-9ABC-1845633F79FB wds:Q90502051-04E62B5B-E5D2-4F76-8DED-AF4DB40FB4C1 wds:Q90502051-0A273932-788E-4D91-AF6E-B4B6DD5589BD wds:Q90502051-0BCE21CD-06BB-4FAF-B0AC-AE29312CFA7A wds:Q90502051-0D297D6F-A128-4CC1-A83F-8DC0199556E5 wds:Q90502051-0EABE439-A4B0-4A7E-BA85-BCF3CBC54A1B wds:Q90502051-1459D5B4-0393-4463-B1B7-985B1520ACFD wds:Q90502051-15705033-3ABB-459E-A4D4-291AB2B37C10 wds:Q90502051-1E8E64C8-D258-466B-8F60-D18E92BBB2D6 wds:Q90502051-1F6F5C11-2D94-43E5-BF0B-8E7D0E2BACC6 wds:Q90502051-1FD35485-CE88-4CF6-9147-7DAC37162BB3 wds:Q90502051-31626668-09FC-45F6-9E58-2E9FCB3AC1E0 wds:Q90502051-329DDD72-8D93-409A-A348-E8D3D8A52F70 wds:Q90502051-3F4F8B9B-E90F-49AF-BC74-58BA34357F1B wds:Q90502051-43EE9569-5D75-482B-A25B-5A960D3C548A wds:Q90502051-4C1D3ADA-F303-4782-8C0B-AAFCEA496F93 wds:Q90502051-4C56AE21-D1F4-4AD0-B754-2C0A9A3AA26D wds:Q90502051-4D18F352-A29F-4C27-8571-9331431862C6 wds:Q90502051-5A31CD27-EBC3-45AE-A8C0-F96FB27E7924 wds:Q90502051-7401F579-1B03-4EE2-ADDE-EEAFECDF6377 wds:Q90502051-7AB1ED63-122B-42EF-937B-303C4C7CFFAF wds:Q90502051-8C4442A5-3EC7-474A-9907-A9085EED5A92 wds:Q90502051-8FAB79C9-469E-42A2-AC38-88C095C6F257 wds:Q90502051-9CF9F5F1-FB66-4563-A934-8A708619891C wds:Q90502051-A9A16892-8B8F-47FF-B312-E63547DDAA1F wds:Q90502051-AE6F3931-D4EF-4DB3-9E2C-161CA5B3A201 wds:Q90502051-AF7FC05E-7666-4F91-ACE5-C58B49A915A2 wds:Q90502051-BD296A8F-B5E0-4B9F-93EF-36C545723E4C wds:Q90502051-CA13F8D0-6D26-4E68-BACB-45D0FF368AB3 wds:Q90502051-D2C699B1-1053-479A-B82F-934894FF078F wds:Q90502051-DC723C7A-C38B-409C-8D3C-2B1218586770 wds:Q90502051-E2418D97-6B34-421E-B517-2EEDF822A2EB
cites work	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis Classification criteria for psoriatic arthritis: development of new criteria from a large international study Measurement of patient outcome in arthritis Predictors for radiological damage in psoriatic arthritis: results from a single centre American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial The MOS 36-ltem Short-Form Health Survey (SF-36) Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year Psoriatic arthritis: epidemiology, clinical features, course, and outcome Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study Psoriatic arthritis Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Development of an assessment tool for dactylitis in patients with psoriatic arthritis Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis Secukinumab: A New Treatment Option for Psoriatic Arthritis Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis Radiographic progression depicted by probability plots: presenting data with optimal use of individual values Focal bone involvement in inflammatory arthritis: the role of IL17. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
author name string	wds:Q90502051-006B5994-19EE-49C0-8CD1-C5FEB3011B65 wds:Q90502051-67E48A5C-5D05-4537-BD0A-EAB677E668A7 wds:Q90502051-6A6C234C-034C-41D0-851D-9C5AFC6E5EC4 wds:Q90502051-8DD893F4-C6C0-4247-9EE6-E95796CBA37E wds:Q90502051-8EF79646-CAA2-4147-969B-5D5B4AEC2A28 wds:Q90502051-95D22095-52B4-4B65-A437-DA870D93B312 wds:Q90502051-A8AF37DC-9FBE-47CB-911B-6987109C0F71 wds:Q90502051-BAD04ADF-16CC-4B61-9A2B-A305416B110E wds:Q90502051-CED1CD49-16D8-4426-AC29-05A2A6E6B1B8 wds:Q90502051-D2276CC8-09E3-46D2-A55B-8A16B83569B3 wds:Q90502051-D9CC8A60-C006-4E47-A317-DF7BD86CD17C wds:Q90502051-DC4B46E4-2E63-4BFD-941D-203A40AF953D wds:Q90502051-F880C8DD-343C-4B6E-883B-77D97A78B343
author name string	Désirée van der Heijde Proton Rahman Philip J Mease Hasan Tahir Atul Singhal Robert B M Landewé Xuan Zhu Gregory Ligozio Aimee Readie Shephard Mpofu Luminita Pricop Sandra Navarra Elke Boettcher
rdfs:label	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5 (en) Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5 (nl)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software